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Abstract
Introduction: Genome-wide association studies, focusing primarily on unilateral breast cancer, have identified
single nucleotide polymorphisms (SNPs) in a number of genomic regions that have alleles associated with a
significantly increased risk of breast cancer. In the current study we evaluate the contributions of these previously
identified regions to the risk of developing contralateral breast cancer. The most strongly disease-associated SNPs
from prior studies were tested for association with contralateral breast cancer. A subset of these SNPs, selected
upon their main effects on contralateral breast cancer risk was further evaluated for interaction with treatment
modalities and estrogen receptor (ER) status.
Methods: We genotyped 21 SNPs in 708 women with contralateral breast cancer and 1394 women with unilateral
breast cancer who serve as the cases and controls in the Women’s Environment, Cancer and Radiation
Epidemiology (WECARE) Study. Records of treatment and ER status were available for most of WECARE Study
participants. Associations of SNP genotypes and risk for contralateral breast cancer were calculated with
multivariable adjusted conditional logistic regression methods.
Results: Multiple SNPs in the FGFR2 locus were significantly associated with contralateral breast cancer, including
rs1219648 (per allele rate ratio (RR) = 1.25, 95%CI = 1.08-1.45). Statistically significant associations with contralateral
breast cancer were also observed at rs7313833, near the PTHLH gene (per allele RR = 1.26, 95%CI = 1.08-1.47),
rs13387042 (2q35) (per allele RR = 1.19, 95%CI = 1.02-1.37), rs13281615 (8q24) (per allele RR = 1.21, 95%CI = 1.04-
1.40), and rs11235127 near TMEM135 (per allele RR = 1.26, 95%CI = 1.04-1.53). The A allele of rs13387042 (2q35)
was significantly associated with contralateral breast cancer in ER negative first tumors while the A allele of
rs11235127 (near TMEM135) was significantly associated with contralateral breast cancer in ER positive first tumors.
Although some SNP genotypes appeared to modify contralateral breast cancer risk with respect to tamoxifen
treatment or particular radiation doses, trend tests for such effects were not significant.
Conclusions: Our results indicate that some common risk variants associated with primary breast cancer also
increase risk for contralateral breast cancer, and that these risks vary with the ER status of the first tumor.
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Patients with breast cancer are two to five times more
likely to develop a second primary cancer in the contral-
ateral breast than are unaffected women to develop an
initial breast cancer [1-4]. Established risk factors for
asynchronous second primary contralateral breast cancer
(CBC) include those suggesting a genetic basis, such as
early age at diagnosis or family history [1], as well as
exogenous factors such as the treatment for the first
breast cancer [5,6]. Prior genome-wide association stu-
dies (GWASs) have identified regions of the genome
containing single-nucleotide polymorphisms (SNPs) with
alleles that are associated with an increased risk for
breast cancer [7-9]. Many of these SNPs were also
reported to be associated with estrogen receptor (ER)-
positive breast cancer [9-11]. For the most part, the spe-
cific causative variants in these regions and their
mechanisms of action remain to be elucidated. In the
present study, we evaluated the contributions of these
identified loci to risk for CBC.
Our study builds on an existing, population-based, epi-
demiologic study of CBC: the Women’s Environment,
Cancer, and Radiation Epidemiology (WECARE) Study.
The WECARE study is a nested case-control study in
which women with CBC (n = 708) serve as cases and
women with unilateral breast cancer (UBC) (n = 1,394)
serve as controls [12]. This study population is well char-
acterized for treatment-related exposures, including radia-
tion therapy (RT) (including dose to the contralateral
breast), chemotherapy, and hormonal therapy, enabling
examination of the interaction of genetic risk factors and
cancer therapy. Previous reports from the WECARE Study
have shown that RT for a first cancer was associated with
an increased risk of CBC [6] but that chemotherapy and
tamoxifen treatment were associated with a lower risk of
CBC [5]. These treatment effects were further modulated
by genetic background. For example, missense variants in
the ATM gene were associated with an increased risk of
CBC in women who were treated with radiation for their
first primary breast tumors [13].
In the present study, we genotyped 21 SNPs represent-
ing 18 genomic regions in the WECARE Study population.
These SNPs were selected on the basis of their having
attained either genome-wide significant evidence or sug-
gestive evidence of association with breast cancer in a
prior GWAS that included at least one replication in a
separate population. Furthermore, we assessed the interac-
tion of these SNPs with radiation dose to the contralateral
breast, chemotherapy, tamoxifen therapy, and ER status.
Materials and methods
Study population
T h eW E C A R ES t u d yi sam u l t i c e n t e r ,p o p u l a t i o n -
based, nested case-control study of 708 cases (women
with asynchronous bilateral breast cancer) and 1,394
controls (women with UBC) recruited through five
population-based cancer registries: one registry cover-
ing all of Denmark and, in the US, one registry cover-
ing Iowa, two registries covering three counties in
Southern California, and one registry covering three
counties in Washington State. The controls were indi-
vidually matched 2:1 to cases on date and age at diag-
nosis of the first primary breast tumors, race, and
registry region and were counter-matched on registry-
reported RT. Each case-control triplet consists of two
women who received RT and one who did not, maxi-
mizing informativeness for radiation exposure [12]. For
12 cases with only one matched control, matched pairs
consisted of one exposed and one unexposed woman
[12]. The WECARE Study protocol was approved by
the institutional review board at each site and the
ethics committee system in Denmark, and informed
consent was obtained from all participants.
Treatments and phenotypes
Medical records were retrieved to obtain detailed infor-
mation on the treatment of the first breast cancer (che-
motherapy, hormonal therapy, and radiotherapy) during
the at-risk period (time between first and second pri-
mary diagnoses) and other tumor characteristics, includ-
ing ER status [5,6].
Radiation dosimetry
Estimated absorbed radiation doses to various specific
contralateral breast locations were reconstructed for
each treatment regimen by using tissue-equivalent phan-
toms and modeling procedures as described previously
[6,12]. Dosage information was available for 604 to 607
cases and 1,184 to 1,195 controls, depending on the
number of genotyped individuals per SNP.
Single-nucleotide polymorphism selection
Twenty-one SNPs were selected from among those most
associated with breast cancer in three prior GWASs
[7-9]. All of these prior studies included at least one
replication in a separate population. Nine of the SNPs
were associated with breast cancer in prior studies at
genome-wide significance levels (P <1 0
-7). These were
rs2981582, rs12443621, rs8051542, rs889312, rs3817198,
and rs13281615 from Easton and colleagues [7];
rs1219648 from Hunter and colleagues [8]; rs13387042
from Stacey and colleagues [9]; and rs3803662 reported
in both Stacey and colleagues [9] and Easton and collea-
gues [7]. The remaining 12 SNPs were described as
showing evidence of association (global P =0 . 0 0 1i n
three populations) in Easton and colleagues [7] and
were listed in the supplemental materials of those
authors.
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Multiplex SNP genotyping was carried out with the Illu-
mina Golden Gate™ assay on the Sentrix Array Matrix
scanned with the Bead Array Reader (Illumina Inc., San
Diego, CA, USA). To avoid any bias in the calling of
genotypes, all DNA samples were coded and laboratory
personnel were blinded to case-control status. A blinded
24% re-sampling was carried out for quality control pur-
poses and these samples were interspersed throughout
the plates. Negative controls lacking DNA were included
on each plate. Results from a subset of SNPs previously
genotyped by an individual SNP method, the MGB
Eclipse™ Probe System (Epoch Biosciences, ELITech
Group, Paris, France), were concordant with the multi-
plex genotyping results. Samples with more than 10%
missing genotypes and SNPs with more than 5% missing
genotypes were excluded from analysis. Although
Hardy-Weinberg equilibrium may not strictly apply
given that all participants in the study were affected
with breast cancer, SNPs deviating from Hardy-Wein-
berg equilibrium with a P value of less than 0.001 were
also excluded.
Haplotyping
Common SNPs (minor allele frequency of greater than
0.1) in the FGFR2 intron 2 region near SNP rs2981582
were selected from the HapMap Project [14]. The Tag-
ger program within Haploview [15] was used to select
SNPs informative for the region with an r
2 of greater
than 0.8. The program PLINK [16] was used to estimate
phase. These tagging SNPs were genotyped with the
MGB Eclipse™ Probe System. In the haplotype analysis,
the referent group for each haplotype consists of those
without that haplotype.
Statistical analysis
The WECARE Study is based on a standard nested case-
control design with the additional feature of counter-
matching on radiotherapy status. All analyses were con-
ducted with multivariable adjusted conditional logistic
regression methods, incorporating an ‘offset term’ or
weight to adjust appropriately for the counter-matched
sampling [12]. For the SNP main effects analysis, P
v a l u ef o rt r e n dw a sf r o mt h el o g - a d d i t i v em o d e l .T h e
test for trend in Table 1 assessed the hypothesis that
CBC risk increases with radiation dose and risk allele
‘dose’. Trend tests had 1 degree of freedom. All analyses
were performed with SAS (Statistical Analysis System)
(SAS Institute Inc., Cary, NC, USA).
Results
The risk of CBC associated with each of the 21 SNPs
from 18 genomic regions selected from prior GWASs of
UBC [7-9] is shown in Table 2. We observed statistically
significant associations with CBC at four of nine SNPs
previously reported to be associated with breast cancer
at genome-wide significance levels (P <1 0
-7): rs2981582
(per-allele rate ratio (RR) = 1.20, 95% confidence inter-
val (CI) = 1.04 to 1.40) and rs1219648 (per-allele RR =
1.25, 95% CI = 1.08 to 1.45) at 10q26 in the FGFR2
gene, rs13281615 in the 8q24 region (per-allele RR =
1.21, 95% CI = 1.04 to 1.40), and rs13387042 in the
2q35 region (per-allele RR = 1.19, 95% CI = 1.02 to
1.37). We observed statistically significant associations
with CBC at two of the remaining 12 SNPs: rs7313833,
located on chromosome 12p in the vicinity of the
PTHLH gene (per-allele RR = 1.26, 95% CI = 1.08 to
1.47), and rs11235127 on chromosome 11q14.2 near
TMEM135 (per-allele RR = 1.26, 95% CI = 1.04 to 1.53).
Excluding BRCA1/2 carriers (who constitute 5.4% of the
WECARE Study population [17,18]) from the present
analysis did not markedly alter the results for any of the
SNPs tested here (data not shown).
To refine the observed association between CBC and
SNPs in the vicinity of FGFR2, we genotyped five haplo-
type-tagging SNPs, in addition to rs2981582, in all 2,102
available WECARE Study participants and found alleles
at four of the six SNPs that were individually associated
with risk of CBC (Additional file 1, Table S1). Whereas
the risk alleles at these SNPs occurred individually on a
number of haplotypes, they occurred together on only
two, of which only one was significantly associated with
an increased risk of CBC (Additional file 1, Table S2).
For SNPs with a P value of less than 0.1 for main
effects in Table 2, we carried out additional exploratory
analyses considering the effect on CBC risk of treatment
or tumor characteristics of the first cancer. Previous stu-
dies have shown that SNP alleles with main effects on
the risk for breast cancer can sometimes be associated
with specific subtypes of breast cancer [10,11,19]. In
Table 3, the association of SNPs with CBC was assessed
for heterogeneity with respect to the ER status of the
first primary tumor. The risk variant at rs13387402
(2q35) was associated with CBC only in individuals with
ER-negative first tumors (interaction P value = 0.0008).
The risk variant at rs11235127 (near TMEM135)w a s
associated with CBC only in individuals with ER-positive
first tumors (interaction P value of not more than 0.01).
There were no significant modifying effects of SNP
genotype on CBC risk associated with radiation dose to
the contralateral breast for those patients receiving RT
for their first cancer (Table 1). Although individual gen-
otypes for SNPs rs3803662 near TOX3 (TNRC9),
rs7313833 near PTHLH, and rs2107425 (H19)a p p e a r e d
to be associated with increased risk for CBC in particu-
lar dose-allele combinations (for example, for rs7313833
minor allele homozygotes at 0.01 to 0.99 Gy radiation,
RR = 2.3, 95% CI = 1.1 to 4.9), there were no obvious
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the SNPs studied significantly modified the effects of
tamoxifen use or chemotherapy (data not shown) on the
incidence of CBC.
Discussion
Breast cancer GWASs have tended to focus on high-risk
individuals such as women from multiple-case breast
cancer families or with early age at onset. The present
study extends findings from these studies by examining
another group of genetically predisposed women, those
with CBC, and considers important treatment co-factors
such as RT, chemotherapy, and hormonal exposures as
well as ER status of the first tumor.
We observed nominally significant associations
between CBC and SNPs in three regions previously
associated with breast cancer, 10q26 (FGFR2), 8q24, and
2q35, all of which had been previously replicated in
Table 1 Risk of contralateral breast cancer associated with radiation dose by single-nucleotide polymorphism
genotype
Homozygous; reference allele Heterozygous Homozygous; risk allele P
value
e
SNP
a/gene
region
RT
dose
b
Cases
c
(CBC)
Controls
(UBC)
RR
d
(95% CI)
Cases
c
(CBC)
Controls
(UBC)
RR
d
(95% CI)
Cases
c
(CBC)
Controls
(UBC)
RR
d
(95% CI)
rs2981582/
FGFR2
0 93 75 1.0 139 119 1.0 66 39 1.0
0 < 1.0 40 172 0.9 (0.6-1.5) 88 253 1.3 (0.9-1.9) 40 108 1.0 (0.6-1.8) 0.39
1.0+ 41 131 1.2 (0.8-2.0) 74 212 1.4 (1.0-2.1) 25 85 0.8 (0.4-1.4)
rs1219648/
FGFR2
0 80 74 1.0 147 117 1.0 71 42 1.0
0 < 1.0 40 165 1.1 (0.7-1.8) 85 256 1.2 (0.8-1.7) 44 112 1.1 (0.7-1.9) 0.37
1.0+ 34 124 1.3 (0.8-2.2) 79 216 1.4 (1.0-2.0) 27 89 0.8 (0.5-1.5)
rs3803662/
TOX3
0 116 115 1.0 141 97 1.0 40 21 1.0
0 < 1.0 85 238 1.6 (1.1-2.3) 66 242 0.9 (0.6-1.3) 17 52 0.9 (0.4-2.0) 0.07
1.0+ 63 199 1.5 (1.0-2.3) 57 175 1.1 (0.7-1.6) 19 54 0.8 (0.4-1.8)
rs13281615/
8q24
0 89 67 1.0 141 128 1.0 70 39 1.0
0 < 1.0 45 159 1.0 (0.6-1.6) 80 269 1.2 (0.9-1.7) 42 103 1.1 (0.6-1.9) 0.99
1.0+ 41 132 1.2 (0.7-2.0) 71 226 1.3 (0.9-1.8) 28 71 1.2 (0.6-2.1)
rs13387042/
2q35
0 66 55 1.0 147 114 1.0 86 62 1.0
0 < 1.0 31 118 1.1 (0.6-1.8) 75 259 1.1 (0.8-1.5) 61 155 1.3 (0.8-2.1) 0.45
1.0+ 34 107 1.1 (0.6-1.9) 59 202 1.1 (0.8-1.7) 46 120 1.4 (0.9-2.2)
rs11235127 0 205 162 1.0 81 66 1.0 13 5 1.0
/TMEM135 0 < 1.0 109 374 1.1 (0.8-1.5) 50 144 1.3 (0.8-2.1) 9 15 0.7 (0.2-3.1) 0.78
1.0+ 91 306 1.2 (0.9-1.6) 39 108 1.3 (0.8-2.3) 9 13 1.1 (0.3-4.3)
rs7313833/
PTHLH
0 124 103 1.0 134 97 1.0 41 31 1.0
0 < 1.0 57 232 1.0 (0.6-1.4) 83 257 1.1 (0.8-1.6) 27 40 2.3 (1.1-4.9) 0.42
1.0+ 56 194 1.1 (0.8-1.7) 62 185 1.2 (0.8-1.8) 21 45 1.7 (0.8-3.6)
rs7696175/
4p14
0 114 72 1.0 127 110 1.0 58 51 1.0
0 < 1.0 65 185 1.0 (0.7-1.6) 77 242 1.4 (1.0-2.0) 26 103 0.9 (0.5-1.7) 0.97
1.0+ 49 141 1.1 (0.7-1.7) 69 208 1.5 (1.0-2.1) 21 79 1.0 (0.5-1.8)
rs2107425/H19 0 132 96 1.0 137 110 1.0 29 27 1.0
0 < 1.0 86 265 1.1 (0.8-1.6) 64 211 1.1 (0.7-1.6) 16 56 1.4 (0.6-3.1) 0.14
1.0+ 60 217 0.9 (0.6-1.4) 66 167 1.6 (1.1-2.3) 14 43 1.5 (0.6-3.5)
aSingle-nucleotide polymorphisms (SNPs) that had a main effect on contralateral breast cancer (CBC) risk with a P value of less than 0.1 were selected for
radiation therapy (RT) dose interaction analysis (rs2107425 did not meet this criterion but is included because of a report [36] that occupational radiation dose
affects rs2107425-associated breast cancer risk).
bRadiation dose to the contralateral breast (mean = 1.1 Gy) in the quadrant where the second primary tumor
occurred.
cTotal number of case subjects and matched control subjects for whom there were location-specific dose estimates ranged from 604 to 607 cases and
1,184 to 1,195 controls, depending on the number of genotyped subjects per SNP.
dRate ratio (RR) adjusted for age at diagnosis of first primary tumor and the
weighting factor that accounts for the counter-matched design.
eOne degree of freedom trend test for modification of radiation dose effect by SNP genotype. CI,
confidence interval; UBC, unilateral breast cancer.
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cancer genome-wide association studies
SNP
a Gene
region
Genotype Cases
(CBC)
Controls
(UBC)
Per-allele rate ratio
b
(95% CI) trend
Heterozygous rate
ratio
b (95% CI)
Homozygous rate
ratio
b (95% CI)
P
value
c
rs2981582 FGFR2 GG 204 449 1.20 (1.04-1.40) 1.26 (0.99-1.60) 1.45 (1.08-1.95) 0.01
AG 351 672
AA 149 268
rs1219648 FGFR2 AA 183 433 1.25 (1.08-1.45) 1.36 (1.07-1.74) 1.55 (1.15-2.08) 0.003
AG 360 676
GG 162 281
rs12443621 TOX3 GG 173 350 1.03 (0.89-1.19) 1.03 (0.80-1.32) 1.06 (0.79-1.42) 0.70
(TNRC9) AG 355 710
AA 177 326
rs8051542 TOX3 GG 215 421 0.96 (0.82-1.11) 0.81 (0.64-1.04) 0.94 (0.70-1.27) 0.57
(TNRC9) AG 344 709
AA 144 261
rs3803662 TOX3 CC 306 640 1.16 (0.99-1.36) 1.08 (0.87-1.35) 1.43 (1.01-2.01) 0.06
(TNRC9) CT 309 606
TT 88 143
rs889312 MAP3K1 AA 343 658 0.99 (0.85-1.17) 0.95 (0.76-1.18) 1.02 (0.70-1.47) 0.93
AC 296 597
CC 67 131
rs3817198 LSP1 AA 320 650 1.08 (0.93-1.27) 1.12 (0.90-1.40) 1.12 (0.79-1.60) 0.31
AG 309 600
GG 76 140
rs2107425 H19 CC 325 673 0.97 (0.83-1.14) 1.01 (0.81-1.25) 0.88 (0.62-1.26) 0.74
CT 311 569
TT 67 146
rs13281615 8q24 AA 201 420 1.21 (1.04-1.40) 1.06 (0.83-1.35) 1.49 (1.11-2.01) 0.01
AG 338 720
GG 166 250
rs30099 5q11 GG 571 1,125 0.92 (0.72-1.18) 0.99 (0.76-1.30) 0.50 (0.18-1.35) 0.50
AG 128 244
AA 8 15
rs4666451 2p24 GG 286 524 0.95 (0.82-1.10) 0.86 (0.68-1.08) 0.96 (0.71-1.31) 0.49
AG 310 669
AA 106 197
rs13387042
d 2q35 GG 152 326 1.19 (1.02-1.37) 1.12 (0.86-1.47) 1.39 (1.04-1.85) 0.02
AG 327 669
AA 225 391
rs11235127 TMEM135 GG 476 977 1.26 (1.04-1.53) 1.12 (0.88-1.41) 2.29 (1.32-4.00) 0.02
AG 194 373
AA 35 39
rs7313833 PTHLH GG 272 616 1.26 (1.08-1.47) 1.24 (1.00-1.55) 1.65 (1.18-2.31) 0.003
AG 329 625
AA 103 139
rs16998733 4q31 GG 556 1,071 0.87 (0.69-1.10) 0.77 (0.59-1.00) 1.48 (0.65-3.37) 0.25
AG 134 291
AA 11 21
rs1318703 16p31 AA 240 485 1.40 (0.90-1.20) 1.06 (0.84-1.34) 1.11 (0.82-1.50) 0.63
AG 327 646
GG 133 234
rs4331913 5p13 GG 247 454 0.98 (0.84-1.14) 0.94 (0.75-1.19) 0.98 (0.72-1.33) 0.77
AG 343 700
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cancer genome-wide association studies (Continued)
AA 116 230
rs4954956 2p21 GG 367 748 1.03 (0.88-1.21) 1.03 (0.83-1.28) 1.06 (0.72-1.57) 0.71
AG 287 532
AA 53 109
rs6469633 8q23 TT 383 791 1.05 (0.88-1.25) 1.11 (0.89-1.38) 0.96 (0.62-1.50) 0.58
TC 278 509
CC 43 86
rs981782 5p12 AA 243 423 0.90 (0.78-1.05) 0.84 (0.67-1.07) 0.84 (0.62-1.12) 0.18
AC 334 693
CC 127 271
rs7696175 4p14 GG 268 457 0.88 (0.76-1.02) 0.89 (0.70-1.11) 0.77 (0.57-1.04) 0.09
AG 319 663
AA 118 266
aSingle-nucleotide polymorphisms (SNPs) selected from among the most significantly associated with breast cancer in the genome-wide association studies by
Easton and colleagues [7], Hunter and colleagues [8], and Stacey and colleagues [9] described further in the ‘Single-nucleotide polymorphism selection’ section of
Materials and methods.
bRate ratio adjusted for age at diagnosis of first primary tumor and counter-matching weight.
cP value with 1 degree of freedom for the
association of per-allele SNP genotype and contralateral breast cancer (CBC) risk.
dFor rs13387402, A is not the minor allele in this study population. CI,
confidence interval; UBC, unilateral breast cancer.
Table 3 Risk of contralateral breast cancer associated with single-nucleotide polymorphism genotypes according to
estrogen receptor status
ER-positive
a ER-negative
a
SNP
b/Gene region Genotype Cases (CBC) Controls (UBC) RR
c (95% CI) Cases (CBC) Controls (UBC) RR
c (95% CI) P value
d
rs2981582/FGFR2 GG 96 232 1.0 64 124 1.0
AG 167 347 1.3 (0.9-1.9) 100 165 1.3 (0.8-2.0) 0.99
AA 73 161 1.6 (1.0-2.3) 28 49 1.3 (0.7-2.3)
rs1219648/FGFR2 AA 81 221 1.0 58 119 1.0
AG 174 354 1.4 (1.0-2.0) 102 169 1.4 (0.9-2.2) 0.74
GG 80 164 1.7 (1.1-2.6) 33 50 1.5 (0.8-2.8)
rs3803662/TOX3 CC 138 331 1.0 89 156 1.0
CT 150 335 1.2 (0.9-1.7) 81 137 1.1 (0.7-1.7) 0.26
TT 47 75 1.8 (1.1-2.9) 23 43 0.9 (0.5-1.7)
rs13281615/8q24 AA 97 222 1.0 51 100 1.0
AG 158 378 1.1 (0.8-1.5) 103 175 1.3 (0.8-2.1) 0.78
GG 82 141 1.4 (0.9-2.1) 38 62 1.2 (0.6-2.2)
rs13387042/2q35 GG 83 169 1.0 31 85 1.0
AG 141 347 0.8 (0.6-1.2) 105 177 1.8 (1.1-3.1) 0.0008
AA 112 224 0.9 (0.6-1.3) 57 73 3.1 (1.7-5.7)
rs11235127/TMEM135 GG 212 538 1.0 138 218 1.0
AG 108 180 1.5 (1.1-2.1) 46 106 0.8 (0.5-1.2) 0.01
AA 17 22 2.5 (1.2-5.3) 9 12 1.0 (0.3-3.0)
rs7313833/PTHLH GG 116 337 1.0 92 155 1.0
AG 168 326 1.5 (1.1-2.0) 76 147 0.9 (0.6-1.4) 0.30
AA 52 71 2.0 (1.2-3.3) 25 32 1.4 (0.7-2.8)
rs7696175/4p14 GG 145 246 1.0 63 111 1.0
AG 141 357 0.8 (0.6-1.0) 97 169 1.0 (0.6-1.6) 0.39
AA 51 135 0.7 (0.4-1.0) 33 55 1.0 (0.5-1.8)
aEstrogen receptor (ER) status of the first primary tumor.
bSingle-nucleotide polymorphisms (SNPs) that had a main effect on contralateral breast cancer (CBC) risk
with a P value of less than 0.1 were selected for ER status interaction analysis.
cRate ratio (RR) adjusted for age at diagnosis of first primary tumor and weighting
factor that accounts for the counter-matched design.
dOne degree of freedom interaction P value. CI, confidence interval; UBC, unilateral breast cancer.
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more strongly associated with bilateral than unilateral
disease in a recent meta-analysis [28].
Our initial genotyping data revealed an association
b e t w e e na nS N Pi nt h eFGFR2 gene (rs2981582) and
CBC with an RR of a magnitude similar to that observed
in the original GWAS report [7]. Further mapping of
the FGFR2 intron 2 region with haplotype-tagging SNPs
in the WECARE Study population suggested that
increased risk for CBC was not restricted to rs2981582
but was associated with a single haplotype, carrying risk
alleles at multiple SNPs, consistent with other reports
[29,30].
Among SNPs genotyped in the WECARE Study which
were as yet unconfirmed in other studies, the strongest
associations with CBC risk were at rs7313833 on chro-
mosome 12p11.22 and at rs11235127 on chromosome
11q14.2. For both of these SNPs, risk was particularly
elevated in homozygotes for the minor allele. Although
these two SNPs were among the 30 most significantly
associated with breast cancer risk in a prior GWAS [7],
the associations had not been previously replicated in
other study populations [31]. The SNP rs7313833 falls
within a small region that is very highly conserved
among mammals but that provides no evidence of being
a coding region itself. The nearest flanking genes are
PTHLH, parathyroid hormone-like hormone, which is
located 28 kb centromeric to the reference SNP, and
KLHDC5, Kelch domain-containing protein 5, which is
located 127 kb telomeric to the reference SNP. In Hap-
Map CEU (Utah residents with Northern and Western
European ancestry from the Centre d’Etude du Poly-
morphism Humain collection) { data, rs7313833 is con-
tained within a region of linkage disequilibrium
extending in the centromeric direction to include the
relatively small PTHLH gene. PTHLH has a broad range
of functions, including roles in mammary gland develop-
ment and tumor progression [32,33], making it a poten-
tial candidate gene. Annotation of KLHDC5 suggests no
obvious connection to breast development or breast
cancer.
On chromosome 11, rs11235127 is not located in an
evolutionarily conserved region, but there are several
uncharacterized, apparently spliced ESTs (expressed
sequence tags) in the region. The nearest annotated
gene is TMEM135, which is located 54 kb centromeric
to the reference SNP and which encodes a transmem-
brane protein that is not well characterized. The nearest
gene in the telomeric direction is RAB38,aR a sf a m i l y
member that is expressed exclusively in melanocytes
and that is located more than 700 kb away. We consid-
ered TMEM135 to be a candidate gene since studies in
the mouse indicate that it is transcriptionally regulated
upon treatment with tamoxifen, an estrogen analog and
therapeutic agent that is associated with a decreased risk
of CBC in the WECARE Study population [34]. How-
ever, we observed no statistically significant modifying
effect of alleles at rs11235127, the SNP located near
TMEM135, or any other SNP studied on the effect of
tamoxifen on CBC risk.
In WECARE Study participants who had received RT,
the mean radiation dose to the contralateral breast dur-
ing treatment was 1.1 Gy. In our previous studies of this
population, we observed that women who were under
40 years of age and who received more than 1.0 Gy of
absorbed dose to a specific quadrant of the contralateral
breast had a significant, 2.5-fold greater risk for CBC
developing in that quadrant than unexposed women [6].
The presence of specific variants in the ATM gene
further increased the risk of CBC specifically in those
women who received RT for their first cancer. Accord-
ingly, in the present study, we assessed whether radia-
tion dose-associated CBC risk was modified by
genotype; owing to small sample numbers in individual
categories, we could not further stratify by age. Overall,
the tests for interaction were not statistically significant,
although some specific genotype-dose combinations
were. For rs3803662 near the TOX3 gene, homozygotes
for the reference allele had a statistically significantly
increased risk for CBC with radiation dose, whereas car-
riers of the minor allele did not show statistically signifi-
cantly increased risk of CBC or dose response.
Currently, the function of TOX3 is not well understood
and its relevance to radiation response is not clear. The
only evident connection between TOX3 and breast can-
cer is that the gene has been implicated in breast tumor
metastasis to bone [35]. Homozygotes for the risk allele
at rs7313833, near PTHLH, who received RT had a sig-
nificantly increased risk of CBC. Interestingly, PTHLH
has also been implicated in breast tumor metastasis to
bone in a mouse model [32]. Owing to a report that
genotype-associated breast cancer risk varied signifi-
cantly by occupational radiation dose (mean of less than
0.05 Gy) for rs2107425 in H19 [36], we evaluated CBC
risk by radiation dose (mean of 1.1 Gy) and rs2107425
genotype. Heterozygotes who received at least 1.0 Gy
were at increased risk for CBC, but there was no statisti-
cally significant trend with dose and genotype.
Previous studies have assessed whether SNP associa-
tions with breast cancer vary with ER status: rs2981582
(in FGFR2), rs3803662 in (TOX3), rs13387042 (in 2q35),
and rs13281615 (in 8q24) were more strongly associated
with ER-positive disease than ER-negative disease
[9,10,27]. In the WECARE Study, only rs13387042 (in
2q35) and rs11235127 (near TMEM135) associations
with CBC risk displayed statistically significant heteroge-
neity with regard to ER status. In our study, 27.4% of
the CBC cases had an ER-negative first primary tumor
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The A allele at rs13387042 was associated with
increased risk of CBC in participants with ER-negative
first tumors. Although an earlier study reported this
allele to be associated with ER-positive disease [9], more
recent meta-analyses have observed significant associa-
tions with both ER-positive and ER-negative disease
[27,37]. Differences in results between the present study
and previous studies could reflect specificity to CBC. No
previous study has examined rs11235127 (near
TMEM135) with regard to ER status.
W h i l et h eW E C A R ES t u d yw a sd e s i g n e dt oe x a m i n e
potential interaction effects of genetic risk factors with
treatment exposures and tumor characteristics, there
are limitations to its application in the context of com-
mon risk factors with modest effects. The WECARE
Study does not include an unaffected (non-cancer)
control population; controls in the study are women
with diagnosed UBC. Although women with CBC
represent a high-risk breast cancer group, the power to
detect main effects of common risk alleles on CBC is
limited by the likely enrichment for these same alleles
among the UBC patients who serve as controls in the
study.
Conclusions
Our study demonstrates that a subset of common var-
iants with moderate effects on breast cancer risk is also
associated with an increased risk for CBC. In particular,
we identified nominally significant associations with
CBC for six of 21 SNPs implicated in prior GWASs of
UBC. Two of these SNPs were significantly associated
with CBC risk, depending on ER status of the first
tumor. Particular combinations of SNP genotypes with
radiation dose were associated with increased risk for
CBC, although there were no statistically significant
interactions with increasing dose and genotype. These
findings underscore the need to consider breast cancer
tumor characteristics and treatment modalities when
examining the risk associated with individual SNPs in
order to help characterize their role in breast
carcinogenesis.
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